Previous 10 | Next 10 |
VANCOUVER, British Columbia, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel multifunctional biotherapeutics, today announced that its board of directors will nominate Dr. Nancy Davidson for election to its board of director...
2023-09-22 10:15:25 ET FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 22, 2023 – USA News Group – Despite the potential federal funding challenges due to the recent debt ceiling deal , optimism in the b...
2023-09-11 03:06:49 ET Summary Zymeworks is a biotech company focused on developing therapies for hard-to-treat cancers. Its lead product, zanidatamab, has shown promising results in clinical trials and has been partnered with larger pharmaceutical companies. The company also ...
2023-09-04 07:46:14 ET Summary Zymeworks, a biotech firm, specializes in biotherapeutics for cancers, with primary product zanidatamab targeting HER2 and collaborations with BeiGene and Jazz Pharmaceuticals. Financially robust with $431.4M cash, revenue surged due to a Jazz deal, ...
2023-08-10 22:19:11 ET Zymeworks Inc. (ZYME) Q2 2023 Earnings Call August 10, 2023 16:30 PM ET Company Participants Diana Papove - Director of Corporate Communications Chris Astle - Senior Vice President and Chief Financial Officer Kenneth Galbraith - Chair and C...
2023-08-10 16:22:24 ET Zymeworks press release ( NASDAQ: ZYME ): Q2 GAAP EPS of -$0.76 misses by $0.27 . Revenue of $7M (+28.7% Y/Y) misses by $9.97M . For further details see: Zymeworks GAAP EPS of -$0.76 misses by $0.27, revenue of $7M misses by $9.97M
Net loss for the first six months of 2023 decrease d by 45% as compared to the same period in 2022 Cash resources of $431.4 million as of June 30, 2023 expected to fund planned operations through at least the end of 2026, and potentially beyond P...
VANCOUVER, British Columbia, July 19, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will report its second quarter 2023 financial results after market close on ...
2023-07-14 05:40:00 ET When looking for stocks that can make one richer, investors often start with names they know. The problem is that the names they know also tend to be the names that everyone knows, and these stocks tend to be valued in such a way that they wouldn't be considered barga...
VANCOUVER, British Columbia, June 29, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced the appointment of Mr. Carlos E. Campoy to its board of directors effective as of June 30, 2023. ...
News, Short Squeeze, Breakout and More Instantly...
VANCOUVER, British Columbia, July 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that manage...
VANCOUVER, British Columbia, June 17, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the Un...
Pursuant to the terms of the licensing agreement between Zymeworks and BeiGene, Zymeworks is entitled to receive an $8 million milestone payment from BeiGene and remains eligible to receive up to $164 million based on additional milestones plus royalties on product sales A Biologics License A...